Eisai Press Release


Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting
Nov 30, 2021 08:56 JST
Eisai Co., Ltd. announced today that the company will conduct a total of 42 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) and in-house discovered and developed E2730 at the 75th American Epilepsy Society Annual Meeting (AES2021), to be held in Chicago, Illinois and virtually from December 3 to 7, 2021.
More info..

European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma
Nov 29, 2021 11:44 JST
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the European Commission has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA.
More info..

European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Nov 29, 2021 09:15 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the European Commission has approved the combination of LENVIMA (KISPLYX in the European Union [EU] for the treatment of advanced renal cell carcinoma [RCC]).
More info..

Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award
Nov 18, 2021 14:28 JST
Eisai Co., Ltd. has announced that it has been selected as the winner of the "Most Liked!" IR Award at the 2021 IR Award, hosted by the Japan Investor Relations Association.
More info..

Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer's Disease
Nov 12, 2021 15:10 JST
Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) announced that data from approximately 7,000 plasma samples from more than 1,800 patients in the ADUHELM (aducanumab-avwa) Phase 3 clinical trials showed a statistically significant correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer's disease.
More info..

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer's Disease (CTAD) Conference
Nov 12, 2021 14:31 JST
Eisai Co., Ltd. and Biogen Inc. announced today results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD).
More info..

Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 12, 2021 14:03 JST
Eisai Co., Ltd. and Biogen Inc. announced a presentation about exploring the use of plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody.
More info..

Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension
Nov 11, 2021 11:05 JST
Eisai Co., Ltd. and Biogen Inc. announced today results of new clinical, biomarker and safety assessments of brain amyloid reduction and five-year clinical status of people living with early Alzheimer's disease (AD) from the lecanemab Phase 2b 201 and the open-label extension (OLE) studies.
More info..

Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer's Disease
Nov 09, 2021 09:46 JST
Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has an agreement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to amend the clinical study (Tau NexGen) design to include a background anti-amyloid agent.
More info..

Eisai and Digital Garage, Inc. Jointly Launch "Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)"
Nov 04, 2021 10:06 JST
Eisai Co., Ltd. announced today that it launches the "Open Network Lab BioHealth Dementia Innovation Challenge (Onlab Bio Dementia)", a collaborative cultivation program jointly implemented with Digital Garage, Inc., with the aim of contributing to solving issues related to dementia and starts recruiting startups for teams to participate in the program.
More info..

Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study
Nov 04, 2021 09:39 JST
Eisai Co., Ltd. announced today the presentation of data from the company's extensive Alzheimer's disease (AD) pipeline, including six oral presentations that will provide deeper insights into lecanemab's potential as a treatment for early AD.
More info..

The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Nov 01, 2021 08:41 JST
Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) / beta-catenin inhibitor E7386, a medium-molecular weight compound created through collaboration research between Eisai and PRISM, has achieved the clinical POC (Proof of Concept).
More info..

Eisai and Merck & Co., Inc. (Kenilworth, N.J.) Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer
Oct 18, 2021 08:00 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted positive opinions recommending approval of the combination of LENVIMA (marketed as Kisplyx in the European Union [EU].
More info..

Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
Sep 28, 2021 10:37 JST
Eisai Co., Ltd. and Biogen Inc. today announced that Eisai has initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company's investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early Alzheimer's disease (early AD).
More info..

Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
Sep 27, 2021 13:50 JST
AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA.
More info..

Eisai to Join The Global Environmental Initiative "RE100"
Sep 14, 2021 16:46 JST
Eisai Co., Ltd. announced today that it has joined "RE100", the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity.
More info..

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
Sep 14, 2021 11:36 JST
Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its oncology products and pipeline will be given at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, from September 16 to 21, 2021, including its in-house discovered lenvatinib mesylate and eribulin mesylate.
More info..

AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients"
Sep 13, 2021 15:37 JST
AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. announced today that, on September 13, 2021, the companies launched "Humira Support Tool Ordering Service for Patients" an initiative intended to improve patients' adherence to Humira therapy.
More info..

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
Aug 31, 2021 08:42 JST
Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand.
More info..

Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma
Aug 16, 2021 09:07 JST
Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide), in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable).
More info..

FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)
Aug 12, 2021 08:31 JST
Eisai and Merck & Co., Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA.
More info..

Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards
Aug 05, 2021 10:45 JST
Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo).
More info..

Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures
Aug 02, 2021 11:24 JST
Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two additional approvals as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older" in China from the National Medical Products Administration.
More info..

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)
Jul 30, 2021 09:07 JST
Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) -- granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021.
More info..

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021
Jul 30, 2021 08:24 JST
Biogen and Eisai Co., Ltd. today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer's disease called ICARE AD-US, at the Alzheimer's Association International Conference (AAIC).
More info..

Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment
Jul 29, 2021 16:34 JST
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 20th consecutive year since its initial inclusion in 2002.
More info..

Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
Jul 27, 2021 08:00 JST
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELMTM (aducanumab-avwa) injection 100 mg/mL solution at the AAIC.
More info..

Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Jul 23, 2021 08:17 JST
Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma.
More info..

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021
Jul 21, 2021 09:34 JST
Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC).
More info..

Latest Release


More Latest Release >>